Business
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Breakthrough Therapies Advance as Rare Disease Burden Intens
About this update from Soligenix, Inc.
[{"type":"image","alt":"Soligenix, Inc.","displaySize":"","headline":null,"caption":"Soligenix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/97065dae627eeea78132a01a8cba3f50"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L6dz0S.Jl7C3J8WTRCjZfg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/97065dae627eeea78132a01a8cba3f50","width":300,"height":82}},"lazy":false},{"type":"text","content":"NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.","length":433,"tagName":"p"},{"type":"text","content":"To view the full publication, “Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations,” please visit: https://ibn.fm/hjy4H ","length":171,"tagName":"p"},{"type":"text","content":"Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs.","length":548,"tagName":"p"},{"type":"text","content":"Soligenix Inc., a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), where it is currently running the final confirmatory trial necessary before seeking global marketing authorization. As the Trump administration pursues new health-policy measures focused on chronic and rare diseases, Soligenix’s programs are positioned at a pivotal crossroads of scientific innovation and national healthcare goals...